As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Adicet Bio, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 9.9%. 11 filings are on record since October 10, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Adicet Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Franklin Templeton, Inc. · Sole voting: 724,138 · Shared voting: 0 · Sole dispositive: 724,138 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-28
- · Reporting person: Zedek Daniel Clayton · Sole voting: 0 · Shared voting: 495,309 · Sole dispositive: 0 · Shared dispositive: 495,309 · SCHEDULE 13G, 2026-10-23
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 935,486 · Sole dispositive: 0 · Shared dispositive: 935,486 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Woodline Partners LP · Percent: 3.3% · SCHEDULE 13G/A
- · Holder: RA Capital Management, L.P. · Percent: 12.3% · SCHEDULE 13G/A
Adicet Bio, Inc. has 11 Schedule 13D or 13G filings on record since 2025-10-10. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.9% | 935,486 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Orbimed Advisors LLC | 8.8% | 844,787 | SCHEDULE 13D/A, 2026-04-10 | 2026-04-08 |
| Franklin Templeton, Inc. | 7.7% | 724,138 | SCHEDULE 13G/A, 2026-10-28 | 2026-09-30 |
| 5.4% | 502,309 | SCHEDULE 13G, 2026-10-23 | 2026-10-19 | |
| Woodline Partners LP | 3.3% | 313,124 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Tang Capital Management, LLC | 0.1% | 6,158 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Adicet Bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Adicet Bio, Inc. and the records around it.
Adicet Bio, Inc. elsewhere on the record
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Adicet Bio, Inc.
Get an email when Adicet Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adicet Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Adicet Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adicet Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 935,486 | 0 | 935,486 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 935,486 | 0 | 935,486 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 935,486 | 0 | 935,486 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 935,486 | 0 | 935,486 | SCHEDULE 13G/A, 2026-08-14 |
| Franklin Templeton, Inc. | 724,138 | 0 | 724,138 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Charles B. Johnson | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Rupert H. Johnson, Jr. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Franklin Advisers, Inc. | 724,138 | 0 | 724,138 | 0 | SCHEDULE 13G/A, 2026-10-28 |
| Zedek Daniel Clayton | 0 | 495,309 | 0 | 495,309 | SCHEDULE 13G, 2026-10-23 |
| Zedek Lauren Marie | 0 | 414,515 | 0 | 414,515 | SCHEDULE 13G, 2026-10-23 |
The latest filing identifies Adicet Bio, Inc. by CUSIP 007002207 and gives its principal executive office as 131 Dartmouth Street, 3rd Floor, Boston, MA 02116 (SCHEDULE 13G/A, 2026-10-28).
What the percentages are based on
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-10; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-10 | Orbimed Advisors LLC | 9.6% | SCHEDULE 13D/A |
| 2026-01-29 | Franklin Resources, Inc. | 6.5% | SCHEDULE 13G |
| 2026-02-17 | Woodline Partners LP | 6.5% | SCHEDULE 13G |
| 2026-02-17 | Tang Capital Management, LLC | 0.1% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-04-10 | Orbimed Advisors LLC | 8.8% | SCHEDULE 13D/A |
| 2026-04-13 | RA Capital Management, L.P. | 12.3% | SCHEDULE 13G/A |
| 2026-05-15 | Woodline Partners LP | 3.3% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-10-23 | Zedek Daniel Clayton | 5.4% | SCHEDULE 13G |
| 2026-10-28 | Franklin Templeton, Inc. | 7.7% | SCHEDULE 13G/A |
Questions about who owns Adicet Bio, Inc.
Who owns Adicet Bio, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Adicet Bio, Inc.: RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Orbimed Advisors LLC (8.8%, Schedule 13D/A, filed 2026-04-10), Franklin Templeton, Inc. (7.7%, Schedule 13G/A, filed 2026-10-28) and Zedek Daniel Clayton (5.4%, Schedule 13G, filed 2026-10-23).
Who are the largest shareholders of Adicet Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Adicet Bio, Inc. on this page are RA Capital Management, L.P. (9.9%), Orbimed Advisors LLC (8.8%) and Franklin Templeton, Inc. (7.7%).
When did RA Capital Management, L.P. buy into Adicet Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Adicet Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.